Evaluation of Magnetic Resonance Imaging-Derived Synthetic Computed Tomography in Prostate Cancer Carbon Ion...

Magnetic resonance imaging (MRI) offers superior soft-tissue contrast for prostate delineation, and MR-only radiotherapy eliminates computed tomography (CT)-MRI registration errors. Although synthetic CT (sCT) has been validated for photon and proton therapy, its clinical feasibility in carbon ion radiotherapy (CIRT) remains unclear, particularly because dose accuracy in CIRT is highly sensitive to stopping-power ratio (SPR) errors. This study evaluated the dosimetric accuracy of MRI-derived sCT for prostate CIRT, including the effect of a thermoplastic fixation shell used clinically but not visualized on MRI.

Twenty patients with prostate cancer underwent same-day planning CT (pCT) and MRI. sCT images were generated using the MRCAT algorithm (Philips Healthcare). Bone pseudo-Hounsfield units were replaced with institution-specific SPR values to improve range accuracy. Treatment plans were created on the pCT and recalculated on the sCT using identical beam parameters. Dose agreement was assessed using carbon-ion depth and lateral dose profiles, 3D gamma analysis (3%/3 mm, 2%/2 mm, 1%/1 mm), and key Dose-volume histogram indices. To evaluate the fixation-shell impact, a 3-mm virtual shell was added to the sCT and compared with a corresponding pCT containing the physical shell.

The sCT-based distal range was longer than that of the pCT by 2.7 ± 1.6 mm, reduced to 1.2 ± 1.6 mm with shell inclusion. Lateral dose differences were <1 mm for all patients. Gamma passing rates exceeded 90% for 2%/2 mm and 3%/3 mm criteria, and the 1%/1 mm pass rate at the 50% threshold improved by ∼6% with shell inclusion. CTV D99% and PTV D1% agreed within ±1%, whereas PTV D95% decreased by up to 8% at the target periphery. Organs at risk (OAR) dose differences were clinically negligible.

With bone SPR adjustment and fixation-shell consideration, Magnetic Resonance for Calculating ATtenuation-based sCT provides clinically acceptable dose-calculation accuracy for prostate CIRT, supporting the feasibility of MR-only planning.